Limited Availability: $799 preorder (reg. $1,299). Save $500. Reserve for $49 →
Reserve Your Test for $49
Warm professional setting with natural light and welcoming atmosphere

Contact Us

Questions about miCheckup? Need help with your order? Our team is here to help — and we respond to every inquiry personally.

Reserve Your Test for $49

Preorder $799 · Regular $1,299 · Save $500

Send us a message.

Whether you have a question about miCheckup, need help with an order, or want to learn more about microRNA multi-cancer early detection — we're here to help.

Whether you have a question about your miCheckup test, need help with an order, or want to learn more about microRNA multi-cancer early detection — reach out anytime.

Email us:
info@micheckup.com

We respond personally to every inquiry within one business day.

Your information is handled in accordance with Canadian privacy legislation (PIPEDA). We never share your details with third parties.

Our Office

Based in Ottawa. Serving all of Ontario.

miRoncol Health is headquartered in Canada's capital — with collection locations across Ontario and national expansion planned.

miRoncol Health Inc. is a Canadian health technology company headquartered in Ottawa, Ontario. Our team includes researchers, physicians, and health professionals dedicated to making multi-cancer early detection accessible to every Canadian.

Mailing address:
miRoncol Health Inc.
1000 Innovation Drive, 5th Floor
Kanata, ON K2K 3E7
Canada

For urgent matters related to an active miCheckup test or results, please email info@micheckup.com with "Urgent" in the subject line and we'll prioritize your inquiry.

View Pricing & Locations
Ottawa Parliament Hill and surrounding greenspace in warm golden light

Have a question? We'd love to hear from you.

Email info@micheckup.com — we respond personally to every inquiry within one business day.

Reserve Your Test for $49

Preorder $799 · Regular $1,299 · Save $500

Important Safety Information

+

miCheckup is intended for adults at or above the age of majority in their province (18 or older in most provinces; 19 or older in British Columbia, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, and Yukon). miCheckup is a multi-cancer early detection (MCED) test — an early warning test intended to identify a suspected cancer signal associated with multiple solid tumor cancers from a single blood draw. miCheckup does not detect all cancers and should be used in addition to routine cancer screening tests recommended by your healthcare provider.

Use of miCheckup is not recommended in individuals who are pregnant or planning pregnancy, under the age of majority in their province, currently undergoing active cancer treatment, or currently experiencing symptoms that may indicate cancer. If you are experiencing symptoms, please consult your physician directly.

Results should be interpreted by a healthcare provider in the context of your medical history, clinical signs, and symptoms. All miCheckup results are reviewed with you by a physician. A result of "no suspected cancer signal identified" does not rule out cancer. A result of "suspected cancer signal identified" is not a diagnosis — it requires confirmatory diagnostic evaluation by medically established procedures, which is why a whole-body MRI and physician follow-up are included in your miCheckup test.

If a suspected cancer signal is identified but cancer is not confirmed with further testing, it could mean that cancer is not present, or that testing was insufficient to detect cancer — including due to the cancer being located in an area or of a type not well represented in the miCheckup signal. False positive results (a suspected cancer signal identified when cancer is not present) and false negative results (no suspected cancer signal identified when cancer is present) do occur.

miCheckup is a complement to, not a replacement for, standard cancer screening programs. Continue all recommended screening — including mammography, Pap/HPV testing, and colorectal screening (FIT or colonoscopy) — as directed by your healthcare provider. Cancer diagnosis in Canada always requires a tissue biopsy confirmed by a pathologist. If a suspected cancer signal is identified, imaging and clinical workup by your healthcare team will determine the actual status. Many findings turn out to be benign after further investigation.

Laboratory/Test Information

+

miCheckup is a multi-cancer early detection (MCED) Laboratory-Developed Test (LDT), performed at an accredited Canadian medical laboratory certified by the Institute for Quality Management in Healthcare (IQMH). In Canada, LDTs are regulated as a clinical laboratory service under provincial and territorial laboratory oversight. Your blood sample is collected, processed, and analyzed entirely within Canada.

The miCheckup microRNA analysis is based on peer-reviewed research published in Scientific Reports (Nature Portfolio, 2024) and Cancers (MDPI, 2022), validated on thousands of peer-reviewed blood samples, with ongoing validation through the Ontario Health Study using 4,000+ Canadian blood samples.

Published validation shows greater than 99% specificity and greater than 90% sensitivity for the majority of cancer types in the current miCheckup panel of multiple solid tumor cancers. Performance may vary by cancer type and individual factors. For a detailed breakdown of sensitivity and specificity by cancer type, and the complete list of cancers currently in the miCheckup panel, visit The Science.

All personal health data is stored in Canada and handled in accordance with the Personal Information Protection and Electronic Documents Act (PIPEDA) and applicable provincial health privacy legislation, including the Personal Health Information Protection Act (PHIPA) in Ontario.

miCheckup is currently available in Ontario, expanding across Canada. For the full safety, regulatory, and performance disclosure, see Important Information.

References

+